Severe Asthma Research Program (SARP)
A National Institutes of Health/ National Heart, Lung & Blood Institutes
The research program in the Fahy laboratory aims to uncover disease mechanisms, develop disease biomarkers, and evaluate novel treatments for airway disease, especially asthma. Our program is truly translational, encompassing clinical trials and investigations in patients and studies of disease mechanisms in cell culture and animal model systems. We have two major areas of activity:
1. In clinical studies we aim to provide a molecular understanding of the clinical heterogeneity of asthma. Our clinical research is enabled by methods we have optimized for application in human studies to advance knowledge about patterns of airway inflammation and remodeling and about the biophysical and biochemical characteristics of pathologic airway mucus.
2. In bench laboratory studies we focus on mechanisms of epithelial cell dysfunction in asthma, including studies of airway mucus. Mucus pathology is an important cause of airway infection and pathologic mucus plug formation in airway disease. Mucin glycoproteins are a key component of airway mucus, and our lab has a specific interest in how mucin glycans participate in mechanisms of microbial adhesion and abnormal mucus rheology.